BioNTech and DualityBio Announce Phase 3 DYNASTY-Breast02 Topline Results
BioNTech and DualityBio announced topline results from the global Phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer.
Story updates
09:03:48 AM UTC
SquawkNews
MAINZ, Germany and SHANGHAI, China, October 26, 2026 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statisti…